Latest news with #ICD
Reuters
22-07-2025
- Business
- Reuters
Emirates goes on a hiring spree for cabin crew, pilots and ground services staff
DUBAI, July 22 (Reuters) - The parent of Emirates airline is looking to expand its workforce by 17,300 including hiring more cabin crew, pilots and engineers as well as cargo, catering and ground handling staff, it said on Tuesday. Emirates Group, owned by Dubai's sovereign wealth fund ICD, plans to add staff in 350 different roles across the group in the financial year that ends next March, expanding its overall workforce by 14%. The new jobs will include over 4,000 at its ground-handling firm dnata, it said. Emirates plays a key role in positioning Dubai as a global centre. Under a 10-year plan known as D33, the city state is seeking to grow its economy by investing in tourism and attracting foreign capital, including into real estate. Home to the world's tallest tower, the city-state welcomed 8.68 million overnight visitors between January and May this year, a rise of 7% from a year earlier, according to government data. As part of the recruiting drive, Emirates will be hosting over 2,100 open days and other talent acquisition events in 150 cities throughout the year, it said in the statement.
Economic Times
15-07-2025
- Business
- Economic Times
Allcargo Terminals to raise Rs 38.28 cr through issuance of 1.32 cr fully convertible warrants
Multimodal logistics operator Allcargo Terminals Ltd (ATL) on Tuesday said it plans to raise Rs 38.28 crore through the issuance of up to 1.32 crore fully convertible warrants to the promoters/promoter group. ADVERTISEMENT The proposed fundraise, which will kickstart ATL's three-year expansion plans, will be utilised for building capacity and setting up new container freight stations (CFS) and inland container depots (ICDs), the company said. An Allcargo group firm, ATL, specializes in CFS and ICD with pan-India presence, serving diverse logistical requirements at strategic locations such as JNPT, Mundra, Chennai, and Kolkata. "The Board of Directors of ATL has approved the preferential allotment in its meeting held on July 15, 2025," Allcargo Terminals said. "As India's logistics sector undergoes structural transformation, ATL is well positioned to scale up operational capacity while remaining capital-efficient and growth-focussed, creating sustainable value for all stakeholders," said Shashi Kiran Shetty, Founder and Chairman, Allcargo Group. Each warrant has a face value of Rs 2 per share, will be issued at an issue price of Rs 29 per warrant with a premium of Rs 27 per warrant, subject to shareholder and regulatory approvals, it stated. ADVERTISEMENT This issuance accounts for approximately 5 per cent of ATL's post-conversion equity share capital and is priced at around 1 per cent premium to the SEBI-defined floor price, as per the company. ATL said its current capacity stands at 8.3-lakh TEUs annually across seven facilities in five hubs that handle approximately 80 per cent of India's EXIM trade. ADVERTISEMENT ATL plans to augment its capacity to over 13-lakh in the coming three years -- by expanding some of its key facilities and by developing new CFS/ICD facilities, the company said. This strategic move is in line with ATL's long-term growth roadmap and will support the company's multi-location infrastructure expansion at Mundra and Nhava Sheva, Greenfield ICD at Farukhnagar and infra upgrades at existing facilities, ATL said. ADVERTISEMENT Currently operating at 80-85 per cent capacity utilisation, the expansion plans will enable the company to cater to future demand and consolidate its leading position in key logistics corridors, the company said. "This expansion comes at a time when our core facilities are operating near full capacity. The proposed expansion in Mundra and Nhava Sheva, greenfield ICD at Farukhnagar and infra upgrades at existing facilities are aligned to strengthen our multimodal footprint," said Suresh Kumar R, Managing Director, Allcargo Terminals Ltd.
Time of India
15-07-2025
- Business
- Time of India
Allcargo Terminals to raise Rs 38.28 cr through issuance of 1.32 cr fully convertible warrants
Multimodal logistics operator Allcargo Terminals Ltd (ATL) on Tuesday said it plans to raise Rs 38.28 crore through the issuance of up to 1.32 crore fully convertible warrants to the promoters/promoter group. The proposed fundraise, which will kickstart ATL's three-year expansion plans, will be utilised for building capacity and setting up new container freight stations (CFS) and inland container depots (ICDs), the company said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Cardiologist Reveals: The Simple Morning Habit for a Flatter Belly After 50! Lulutox Undo An Allcargo group firm, ATL, specializes in CFS and ICD with pan-India presence, serving diverse logistical requirements at strategic locations such as JNPT, Mundra, Chennai, and Kolkata. "The Board of Directors of ATL has approved the preferential allotment in its meeting held on July 15, 2025," Allcargo Terminals said. "As India's logistics sector undergoes structural transformation, ATL is well positioned to scale up operational capacity while remaining capital-efficient and growth-focussed, creating sustainable value for all stakeholders," said Shashi Kiran Shetty, Founder and Chairman, Allcargo Group. Live Events Each warrant has a face value of Rs 2 per share, will be issued at an issue price of Rs 29 per warrant with a premium of Rs 27 per warrant, subject to shareholder and regulatory approvals, it stated. This issuance accounts for approximately 5 per cent of ATL's post-conversion equity share capital and is priced at around 1 per cent premium to the SEBI-defined floor price, as per the company. ATL said its current capacity stands at 8.3-lakh TEUs annually across seven facilities in five hubs that handle approximately 80 per cent of India's EXIM trade. ATL plans to augment its capacity to over 13-lakh in the coming three years -- by expanding some of its key facilities and by developing new CFS/ICD facilities, the company said. This strategic move is in line with ATL's long-term growth roadmap and will support the company's multi-location infrastructure expansion at Mundra and Nhava Sheva, Greenfield ICD at Farukhnagar and infra upgrades at existing facilities, ATL said. Currently operating at 80-85 per cent capacity utilisation, the expansion plans will enable the company to cater to future demand and consolidate its leading position in key logistics corridors, the company said. "This expansion comes at a time when our core facilities are operating near full capacity. The proposed expansion in Mundra and Nhava Sheva, greenfield ICD at Farukhnagar and infra upgrades at existing facilities are aligned to strengthen our multimodal footprint," said Suresh Kumar R, Managing Director, Allcargo Terminals Ltd.
&w=3840&q=100)
Business Standard
15-07-2025
- Business
- Business Standard
Allcargo Terminals to raise ₹38.28 cr through convertible warrants issuance
"The Board of Directors of ATL has approved the preferential allotment in its meeting held on July 15, 2025," Allcargo Terminals said Press Trust of India Mumbai Multimodal logistics operator Allcargo Terminals Ltd (ATL) on Tuesday said it plans to raise Rs 38.28 crore through the issuance of up to 1.32 crore fully convertible warrants to the promoters/promoter group. The proposed fundraise, which will kickstart ATL's three-year expansion plans, will be utilised for building capacity and setting up new container freight stations (CFS) and inland container depots (ICDs), the company said. An Allcargo group firm, ATL, specializes in CFS and ICD with pan-India presence, serving diverse logistical requirements at strategic locations such as JNPT, Mundra, Chennai, and Kolkata. "The Board of Directors of ATL has approved the preferential allotment in its meeting held on July 15, 2025," Allcargo Terminals said. "As India's logistics sector undergoes structural transformation, ATL is well positioned to scale up operational capacity while remaining capital-efficient and growth-focussed, creating sustainable value for all stakeholders," said Shashi Kiran Shetty, Founder and Chairman, Allcargo Group. Each warrant has a face value of Rs 2 per share, will be issued at an issue price of Rs 29 per warrant with a premium of Rs 27 per warrant, subject to shareholder and regulatory approvals, it stated. This issuance accounts for approximately 5 per cent of ATL's post-conversion equity share capital and is priced at around 1 per cent premium to the SEBI-defined floor price, as per the company. ATL said its current capacity stands at 8.3-lakh TEUs annually across seven facilities in five hubs that handle approximately 80 per cent of India's EXIM trade. ATL plans to augment its capacity to over 13-lakh in the coming three years -- by expanding some of its key facilities and by developing new CFS/ICD facilities, the company said. This strategic move is in line with ATL's long-term growth roadmap and will support the company's multi-location infrastructure expansion at Mundra and Nhava Sheva, Greenfield ICD at Farukhnagar and infra upgrades at existing facilities, ATL said. Currently operating at 80-85 per cent capacity utilisation, the expansion plans will enable the company to cater to future demand and consolidate its leading position in key logistics corridors, the company said. "This expansion comes at a time when our core facilities are operating near full capacity. The proposed expansion in Mundra and Nhava Sheva, greenfield ICD at Farukhnagar and infra upgrades at existing facilities are aligned to strengthen our multimodal footprint," said Suresh Kumar R, Managing Director, Allcargo Terminals Ltd.
Medscape
15-07-2025
- Health
- Medscape
Testing for LMNA Mutations Called ‘Woefully Underutilized'
People with mutated copies of the LMNA gene are at high risk for cardiac laminopathies, including atrioventricular block and atrial or ventricular arrhythmias (VAs) leading to dilated cardiomyopathy. These autosomal dominant mutations have a high penetrance, meaning that a high percentage of persons with a pathogenic or likely pathogenic variant will develop health problems related to the gene. For those with cardiac manifestations, about 90% of carriers of LMNA mutations older than 30 years have a high risk for sudden death from arrhythmia — even patients with minimal left ventricular dilation and mild systolic impairment — well before the onset of heart failure. A long-term follow-up study from 122 consecutive carriers of LMNA mutations with cardiac conditions showed that most had experienced arrhythmia, heart block, embolic events, or heart failure within 7 years of diagnosis. Could some outcomes, such as sudden cardiac death, be averted with a more precise view of LMNA mutations? New research published in JAMA Cardiology shows pinpointing the type and location of the LMNA mutation may guide clinicians toward earlier treatment approaches to improve prognosis for these high-risk patients. These interventions might include earlier placement of implantable cardioverter-defibrillator (ICD) devices and family testing to detect the mutation before the onset of symptoms. 'Genetic testing for dilated cardiomyopathy is woefully underutilized,' said the paper's senior author, Neal Lakdawala, MD, an associate professor of medicine at Harvard Medical School and a cardiologist in the Heart and Vascular Center at Brigham and Women's Hospital, in Boston. In fact, claims data showed that fewer than 2% of patients with dilated cardiomyopathy undergo genetic testing. 'Prior research has established the prognostic power of a genetic diagnosis,' Lakdawala told Medscape Medical News . 'We took it one step further within a specific genetic etiology, to show that the type of gene variant and the location of a gene variant also matter.' The retrospective cohort study examined international registry data from 718 patients (mean age, 41.3 ± 14.3 years) with pathogenic or likely pathogenic variants of LMNA . The participants in the study had no prior history of malignant VA. The primary outcome was time to malignant VA, defined as sudden cardiac death, placement of an ICD, or other manifestations of hemodynamically unstable VA. The secondary outcome, advanced heart failure, was defined as nonsudden cardiac death, implantation of a left ventricular assist device, or heart transplant. Reflecting the high risk associated with LMNA mutations, Lakdawala said, nearly one third of the study participants experienced sudden cardiac death, hemodynamically unstable VA, or an ICD procedure during the 4.2-year follow-up period. In addition, 15% developed advanced heart failure, defined as the implantation of a left ventricular assist device, heart transplant, or nonsudden cardiac death. These outcomes occurred despite many patients having a baseline left ventricular ejection fraction (EF) in the normal range (mean EF was 56%, well above guideline-recommended thresholds of 35%-45% for ICD placement, the researchers reported). Looking deeper into the genes, Lakdawala and his colleagues found participants who had truncating LMNA variants — an abbreviated version of the protein — had worse arrhythmic outcomes, regardless of the position of this genetic mutation on the DNA sequence. On the other hand, those who exhibited missense variants of the LMNA gene — an altered amino acid on the DNA sequence — had a lower risk for harmful arrhythmias and better overall outcomes. Taken together, the location and nature of the gene variants could lead to specific predictions of cardiac risk, according to the researchers. A man with an EF of 50% and a truncating LMNA gene variant, for example, would have a 12% risk for VA within 5 years, but a 7.2% risk if a missense variant were present. For a woman with EF 50%, this risk would be 7.5% for a truncating variant vs 4.5% for a missense variant, if no other risk factors were present. Why Genetic Testing Is Key In an editorial accompanying the journal article, Sharlene M. Day, MD, a cardiomyopathy specialist and presidential professor at the Perelman School of Medicine at the University of Pennsylvania, in Philadelphia, wrote 'the data from this study can also inform risk stratification even in healthy populations with incidental or secondary findings.' Integrating genetic findings into cardiomyopathy management should be 'a priority for all practicing cardiologists,' she wrote. 'The knowledge gap appears to be narrowing with respect to the importance of genetic testing in patients with cardiomyopathies,' Day told Medscape Medical News . 'But there's still opportunity to improve recommendations and referrals by cardiologists for genetic counseling and testing.' Testing typically consists of a broad panel identifying multiple gene variants, including LMNA , she said. If a gene variant is found in an individual patient, cascade testing of family members for that variant is often recommended. 'The current research study nicely highlights the impact of identifying not only the specific gene involved but the type of variation within that gene in terms of risk stratifying patients for adverse outcomes,' she said. Impact on Future Cardiology Guidelines Future clinical practice guidelines should emphasize the value of a genetic diagnosis for risk stratification in patients with dilated cardiomyopathy, especially for predicting sudden death and heart failure, Lakdawala said. The most recent guidelines on heart failure from the American College of Cardiology and the American Heart Association list a class 2A recommendation for placement of an ICD in patients with high-risk genes for dilated cardiomyopathy and an EF of 45% or lower, adding that primary preventive ICD may be considered for those with higher EF. The 2023 European Cardiomyopathy Guideline recommends placement of ICDs in patients with LMNA variants and an EF above 35% (class 2A if risk factors are present and class 2B if no risk factors are present). 'For updated guidelines, I think the most immediate impact would be to refine the LMNA risk score for ventricular arrhythmias to include the type and location of the LMNA variant,' Day told Medscape Medical News . 'Genetic testing has clinical ramifications that will help cardiologists take better care of their patients,' Lakdawala added. 'The take-home message is that they should order these tests!' Lakdawala reported receiving personal fees from Alexion, Bayer, Bristol Myers Squibb, Cytokinetics, Lexeo Therapeutics, Nuevocor, Pfizer, and Tenaya Therapeutics and grants from Bristol Myers Squibb and Pfizer. Day reported serving as chair of the steering committee for Lexicon Pharmaceuticals, on the data monitoring committee for Cytokinetics, and receiving grants from Bristol Myers Squibb.
